N4 Pharma Reports Encouraging IBD Study Results for Nuvec® Drug Delivery Platform

 

N4 Pharma (LSE:N4P) has released promising early results from its first in vivo study under the N4 101 program, which is focused on an oral anti-inflammatory therapy for Inflammatory Bowel Disease (IBD) utilizing its proprietary Nuvec® delivery system. The study showed a notable reduction in inflammation and enhanced therapeutic impact when targeting specific cells, highlighting Nuvec®’s potential as a cutting-edge nucleic acid delivery platform.

These results mark an important milestone for N4 Pharma, potentially opening doors to deeper engagement with prospective commercial partners and providing a solid foundation as the company moves toward further stages of preclinical and clinical development.

About N4 Pharma

N4 Pharma is a preclinical biotechnology firm specializing in Nuvec®, its unique gene delivery technology platform designed for nucleic acid-based therapies. The company is actively building a strong body of preclinical evidence to support its goal of entering human trials and securing high-value licensing deals with partners in gene and cancer therapy development.

• Average Daily Trading Volume: 1,744,751 shares

• Technical Sentiment: Sell

• Market Capitalization: £8 million

CLICK HERE TO REGISTER FOR FREE ON ADVFN, the world's leading stocks and shares information website, provides the private investor with all the latest high-tech trading tools and includes live price data streaming, stock quotes and the option to access 'Level 2' data on all of the world's key exchanges (LSE, NYSE, NASDAQ, Euronext etc).

This area of the ADVFN.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ADVFN Ltd. ADVFN Ltd does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ADVFN.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ADVFN.COM and is not intended to be relied upon by users in making (or refraining from making) any investment decisions. Authors may or may not have positions in stocks that they are discussing but it should be considered very likely that their opinions are aligned with their trading and that they hold positions in companies, forex, commodities and other instruments they discuss.

Comments are closed

WHAT IS ADVFN?

ADVFN covers all things stock market.

From the news and opinion pieces on pages like this to share discussion forums, charting tools, financials, live share prices and Level 2, order book data

If you trade or invest ADVFN has the tools you need to make the right decisions.

• 

  101 Ways to Pick Stock Market Winners

  You need the number one bestselling investment guide, the definitive text for day traders, investors and stock pickers.

• 

  The Death of Wealth

  Dissecting the global economy and the financial markets, the book lays out the evidence for the next economic game changer: the Death of Wealth.

• 

  getbux

• 

  Clem Chambers

• 

  Kiana Danial

• 

  gurely